One of the major challenges in neuroscience is to identify the changes which accompany aging and which contribute to the well-documented age-related deterioration in cognitive function. This is a particular challenge in the light of the vast array of reported changes, which include morphological changes like synaptic and perhaps cell loss, alteration in membrane composition and the resultant changes in function of membrane proteins, modulation of the hypothalamo-pituitary axis, impaired calcium homoeostatic mechanisms, alteration in enzyme function and decreased neurotransmitter release. In the past few years, evidence suggesting that an aged brain exhibits signs of oxidative stress and inflammatory stress has been accumulating, and recent evidence using microarray analysis has added support to this view. In this paper, we provide evidence to suggest that vitamin D 3 acts as an anti-inflammatory agent and reverses the age-related increase in microglial activation and the accompanying increase in IL-1β (interleukin-1β) concentration.
Increased IL-1β (interleukin-1β) concentration in hippocampus is associated with deficits in synaptic function
Cognitive deficits in aged rats, particularly deficits in spatial information processing, have been consistently reported by several groups for many years; thus it has been demonstrated that spatial learning, for example using the Morris Water maze, is reduced in aged rats [1] . Correlated with deficits in performance in spatial learning is a deficit in LTP (long-term potentiation) in hippocampus, a form of synaptic plasticity which is considered to be a biological substrate of learning and/or memory [2] . Among the changes which correlate with the age-related impairment in LTP is an increase in accumulation of ROS (reactive oxygen species) in hippocampus [3, 4] which is indicative of oxidative stress, and a great deal of evidence accumulated in the past few years has coupled this with changes which are indicative of inflammation. These are characterized by an increase in hippocampal concentration of the pro-inflammatory cytokine IL-1β [5] , which has been shown to be inversely correlated with the ability of rats to sustain LTP [6] . Significantly, an increase in hippocampal IL-1β concentration has been reported in rats treated with LPS (lipopolysaccharide) or Aβ (amyloid β) protein, and in rats exposed to irradiation as well as aged rats [7] [8] [9] [10] . In each of these experimental conditions, LTP is decreased and IL-1β-induced cell signalling is up-regulated. Evidence indicates that IL-1β-induced activation of JNK (c-Jun Nterminal kinase) significantly contributes to the LPS-and Aβ-associated deficit in LTP since treatment of rats with the peptide inhibitor of JNK, D-JNKI1, suppresses the inhibitory effects of both on LTP [7, 11] . This is supported by the findings of a number of studies which have revealed that when the age-related increase in IL-1β concentration is suppressed, and consequently when LTP is restored, the accompanying increase in activation of JNK is reversed. For example, treatment of rats with the polyunsaturated fatty acid, eicosapentaenoic acid which possesses anti-inflammatory properties, has been shown to abrogate the age-related, irradiation-induced and LPS-induced changes in IL-1β concentration and LTP and the associated change in JNK activation [8, 10, 12] . Similarly, treatment of rats with phosphatidylserine-bearing liposomes, which suppressed the LPSinduced increase in IL-1β concentration, also blocked the associated increase in JNK activation [13] .
What is the cell source of IL-1β?
It is generally accepted that the primary cell source of IL-1β is activated microglia [7, 14, 15] and therefore, it might be predicted that microglial activation will accompany the age-related increase in hippocampal IL-1β concentration. However, although several studies have reported increased microglial activation in neurodegenerative diseases like AD (Alzheimer's disease) [16] and in animal models of AD [17] , the evidence indicating an increase in activated microglia in the aged brain is equivocal. Whereas an increase has been reported in primates [18] , there are conflicting reports relating to changes in aged rodents, with increased microglial activation in rat hippocampus being reported by some groups [19] but not others [20] .
IL-10 concentration is decreased in the hippocampus of the aged rat
Associated with the age-related increase in hippocampal concentration of IL-1β is an age-related decrease in the concentration of the anti-inflammatory cytokine, IL-10. IL-10, like IL-1β, is a pleiotropic cytokine that regulates a variety of functions of haemapoietic and non-haemapoietic cells [21] , and its receptor is expressed on a wide range of cells including neurons [22] . Significant expression of the receptor has been observed in several brain areas [23] , which explains the effect of IL-10 on central functions; for example, IL-10 has been shown to reverse the IL-1-induced fever which follows LPS injection [24] , and to antagonize the effect of IL-1β on sleep [25] . At the level of the hippocampus, where receptors have also been identified, IL-10 has been shown to attenuate the effects of traumatic brain injury which have been attributed to an increase in IL-1β, and this was associated with a decreased concentration of IL-1 in the hippocampus [26] . The evidence indicates that IL-10 inhibits the actions of IL-1β, at least in some cases by inhibiting IL-1β production and/or release (see [27] ), and this effect has been observed in the hippocampus, where it also decreases IL-1RI expression and IL-1β-induced cell signalling [28] . Whereas LPS has been shown to increase hippocampal concentration of IL-1β mRNA and protein, IL-10 antagonizes these effects, and the inhibition of LTP induced by treatment of rats with IL-1β or LPS has been shown to be abrogated by IL-10 [28] . In some cells, IL-10 may exert its actions by increasing the expression of IL-1 receptor antagonist production, for example in LPSstimulated human polymorphonuclear leucocytes [29] , but a similar effect in hippocampus has not been observed [28] . The findings of some studies have suggested that a significant component of the anti-inflammatory effect of IL-10 may be linked with its ability to modulate microglial function and to inhibit the subsequent cytokine production by microglia [30, 31] . Consistently, IFNγ (interferon-γ )-induced activation of microglia has been shown to be down-regulated by IL-10 [30] .
Evidence that vitamin D 3 possesses anti-inflammatory properties
It has been established that the role of vitamin D 3 extends beyond its traditional role in bone metabolism [32] and is capable of modulating immune function by acting on its receptor, the vitamin D receptor [32, 33] , which is expressed on several cell types, especially cells of the immune system [34] . Vitamin D 3 has been shown to reduce the inflammatory changes associated with delayed hypersensitivity, inflammatory bowel disease and experimental encephalomyelitis, and this has been attributed to the fact that the anti-inflammatory cytokines, transforming growth factor and IL-4, were increased by vitamin D 3 , while the pro-inflammatory cytokines, IFNγ and tumour necrosis factor-α, were reduced [33, 34] . On the basis of these findings it might be predicted that the anti-inflammatory effects of vitamin D 3 may extend to the hippocampus and therefore that some of the inflammatory changes induced by age in the hippocampus might be attenuated by treatment of aged rats with vitamin D 3 . To assess this, young and aged rats were subdivided into two groups, an experimental group which received vitamin D 3 in their diet for 2 weeks and a control group which received standard laboratory chow. At the end of the 2 week treatment period, hippocampal tissue was analysed for evidence of microglial activation using phenotypic and functional markers. For phenotypic markers, tissue was assessed for expression of two markers of microglial activation, CD11b and MHCII (major histocompatability complex II), and IL-1β concentration was assessed as a functional marker of microglial activation. We also assessed hippocampal concentration of IL-10 in an effort to establish whether vitamin D 3 might exert its putative antiinflammatory effect by increasing IL-10 concentration.
Evidence of age-related increase in microglial activation: effect of vitamin D 3
The data presented in Figure 1 indicate that the number of cells expressing MHCII was markedly increased in sections prepared from aged (iii) compared with young (i) controltreated rats and that, while vitamin D 3 treatment exerted no significant effect in young rats (ii), it reduced the age-related increase in the number of cells that expressed MHCII (iv). In a striking parallel, the data also indicate that CD11b expression was increased in aged (vii), compared with young (v), controltreated rats, whereas CD11b expression was decreased in aged rats that received vitamin D 3 (viii); no marked effect of treatment was observed in young rats (vi). These data indicate that, on the basis of phenotype, there is an age-related increase in microglial activation, and that vitamin D 3 treatment abrogated the age-related change.
Effect of vitamin D 3 treatment on the age-related increase in IL-1β concentration
One functional marker of increased activation of microglia is the consequent increase in IL-1β, and in an effort to confirm the phenotypic data, the hippocampal concentration of IL-1β was assessed in tissue prepared from aged and young control-and vitamin D 3 -treated rats. The data indicate that mean hippocampal IL-1β concentration was significantly increased in tissue prepared from aged, compared with young, rats (P < 0.05; ANOVA: Figure 2(a) , while the concentration of IL-1β was similar in tissue prepared from young rats and aged vitamin D 3 -treated rats, and significantly lower in tissue prepared from aged vitamin D 3 -treated, compared with aged control-treated rats (P < 0.01; ANOVA). It has been shown that increased IL-1β concentration in hippocampus is accompanied by a number of markers of deterioration in cell function. One of these markers is an increase in cleavage of DNA repair enzyme, PARP [poly(ADP-ribose) polymerase]. Here, we assessed expression of the cleaved (85 kDa) form of PARP using Western immunoblotting and show that there was a significant age-related increase in expression of 85 kDa PARP (P < 0.01; ANOVA; Figure 2b ), which was completely abrogated in tissue prepared from vitamin D 3 -treated rats. Thus expression in this tissue was similar to that in tissue prepared from young rats and it The concentrations of IL-1β and IL-10, and PARP cleavage were assessed in hippocampal homogenate by ELISA and Western immunoblotting respectively as previously described [28] . Mean IL-1β concentration (a) and 85 kDa PARP expression (b) were significantly increased in hippocampal tissue prepared from control-treated aged, compared with young, rats (*P < 0.05, **P < 0.01; ANOVA); treatment with vitamin D 3 (0.1 µg/ml) attenuated this age-related change. Mean IL-10 concentration was significantly decreased in tissue prepared from control-treated aged rats compared with young rats (*P < 0.05; ANOVA; c and d); treatment with vitamin D 3 alone did not induce any change (c) but, in combination with dexamethasone (1 µg/ml in drinking water; d) it completely reversed the change so that mean IL-10 concentration in tissue prepared from treated aged rats was significantly increased compared with that in control-treated aged rats (***P < 0.001; ANOVA). Data are expressed as means ± S.E.M for six estimations.
was significantly reduced compared with that in tissue prepared from control-treated aged rats (P < 0.01; ANOVA).
Does the anti-inflammatory effect of vitamin D 3 extend beyond its effect on IL-1β?
These data suggest that vitamin D 3 exerts anti-inflammatory effects and in an effort to establish whether this is a consequence of increased hippocampal concentration of IL-10, cytokine concentration was assessed in aliquots of the same tissue in which IL-1β concentration was assessed. Figure 2(c) indicates that mean IL-10 concentration was decreased in hippocampal tissue prepared from aged, compared with young, rats (P < 0.05; ANOVA), but that treatment of rats with vitamin D 3 failed to exert any significant effect in aged or young rats, therefore, the significant age-related decrease persisted in this treatment group (P < 0.05; ANOVA). In contrast with this, treatment of aged rats with a combination of vitamin D 3 and the synthetic glucocorticoid, dexamethasone, which has been shown to increase IL-10 concentration in peripheral tissues [35] , reversed the age-related decrease in IL-10 concentration restoring it to that observed Figure 3 The LPS-induced increases in microglial activation and IL-1β are blocked by IL-10 Cultured cortical glia were incubated in the absence or presence of LPS (100 ng/ml in neurobasal medium) with or without a 1 h pretreatment with IL-10 (100 ng/ml in neurobasal medium). Supernatant was removed and used for analysis of IL-1β concentration and cells were fixed and analysed for expression of MHCII using OX-6 staining; details of the methodology have been published [13] . ( in hippocampal tissue prepared from young rats. These findings are similar to those which have been reported in peripheral tissues. While vitamin D 3 has been shown to inhibit pro-inflammatory cytokine production [36] , the combination of dexamethasone and vitamin D 3 can induce naive T-cells to differentiate into IL-10-producing T regulatory cells [35, 37] and to induce maturation of dendritic cells which in turn secrete IL-10 [38] .
We argued that, if the increase in production of IL-1β is dependent on the presence of activated microglia then parallel changes in microglial activation and increased IL-1β concentration must be predicted. To examine this prediction and to further explore the potential of IL-10 to modulate microglial activation, we assessed the effect of LPS, in the presence and absence of IL-10, on MHCII expression and IL-1β concentration in cultured cortical glial cells. Cells were prepared from 1-day old Wistar rats and treated with LPS in the presence or absence of IL-10; supernatant was collected for analysis of IL-1β and cells were stained for evidence of MHCII expression. Figure 3(a) indicates that the number of cells which stained positively for MHCII was markedly increased in LPS-treated (ii) cultures compared with control (i), and IL-10 abrogated the LPS-induced upregulation of MHCII expression (iv), while IL-10 alone exerted no marked effect (iii). These data provide evidence based on phenotype, that microglial activation was increased and suggest that IL-10 abrogates the LPS-induced change. In parallel with this, and consistent with the idea that IL-10 modulates microglial activation, is the finding that the significant LPSinduced increase in IL-1β (P < 0.05; ANOVA; Figure 3b ) was also inhibited by treatment of cells with IL-10. The data presented here indicate that IL-10 exerts a neuroprotective effect, which is consistent with our earlier observations which demonstrated that IL-10 antagonized the LPS-induced upregulation of IL-1RI, IL-1β mRNA and protein and IL-1β-stimulated cell signalling [9, 28] . The present findings suggest that these effects may be secondary to the modulatory effect of IL-10 on microglial function.
An anti-inflammatory role for vitamin D 3 has been recognized for some time and it has been specifically identified as exerting protection in conditions which are associated with polarization of T-cell responses to the Th1 phenotype [33, 34] . In this paper, we have highlighted the fact that the modulatory effects of vitamin D 3 extend to the hippocampus and specifically that treatment of aged rats with vitamin D 3 attenuates the age-related up-regulation of inflammatory cytokines coupled with down-regulation of anti-inflammatory cytokines, which we have consistently shown to be associated with impairment in cognitive function.
